DXCM Stock Analysis — Dexcom
Sector: Healthcare
AI Verdict
Dexcom trades at 24.6x next year's earnings for 30.1% growth, which is cheap for a medtech leader with real switching costs, but the stock's recent underperformance means execution must stay flawless.
Competitive Moat
Dexcom dominates the continuous glucose monitoring market with proprietary sensor technology and deep integration into diabetes management platforms, making it difficult for new entrants to match their accuracy and ecosystem. Their long-term data partnerships with healthcare providers and device makers create switching costs for both patients and clinicians.
Summary
Dexcom's forward P/E of 24.6x with 30.1% expected EPS growth puts it in rare territory for medical device stocks.
Where It Stands
Shares are down -11.58% over the past year, RSI sits at a neutral 52.3, and the stock trades at 24.6x forward earnings versus the healthcare sector median of 22x.
Key Metrics
- RSI: 52.3 — Neutral
- Trailing P/E: 31.9x
- Forward P/E: 24.6x
- PEG Ratio: 1.08
- Earnings Growth: +0.3%
- Revenue Growth: +0.2%
- Market Cap: $28.6B
- 1-Year Return: -11.58%
- 52-Week High: $89.98
- 52-Week Low: $54.11
Analyst Consensus
33 Buy · 5 Hold · 0 Sell (38 analysts)
Bull Case
With analysts projecting 30.1% EPS growth and a forward P/E of 24.6x, you're paying less than 1x expected growth for a business with entrenched device and data moats.
Bear Case
If the forward P/E compresses to the sector median of 22x, shares would drop about 11% from here, and last year's -11.58% return shows the market is quick to punish any growth wobble.
Catalyst to Watch
Watch for FDA approvals or major payer coverage decisions on new sensors—positive updates could justify the premium multiple.